Platelets and platelet-derived microvesicles as immune effectors in type 2 diabetes.

Platelets and platelet-derived microvesicles as immune effectors in type 2 diabetes.
Curr Vasc Pharmacol. 2017 Jan 26;
Authors: Cortez-Espinosa N, Mayoral LP, Perez-Campos E, Fuentes HA, Mayoral EP, Martínez-Cruz R, Canseco SP, Andrade GM, Cruz MM, Velasco IG, Cruz PH
Abstract
The association between type 2 diabetes mellitus (T2DM) and systemic inflammation may increase platelet reactivity and the accelerated development of vascular disease. Platelets are able to modulate the function of immune cells via the direct release of growth factors and pro-inflammatory chemokines through the production of microvesicles. The microvesicles trigger a transcellular delivery system of bioactive molecules to other cells acting as vectors in the exchange of biological information. Here, we consider the influence of platelets and platelet-derived microvesicles on cells of the immune system and the implications in the pathogenesis of T2DM.
PMID: 28128064 [PubMed - as supplied by publisher]

Source: Current Vascular Pharmacology - January 25, 2017 Category: Drugs & Pharmacology Authors: Cortez-Espinosa N, Mayoral LP, Perez-Campos E, Fuentes HA, Mayoral EP, Martínez-Cruz R, Canseco SP, Andrade GM, Cruz MM, Velasco IG, Cruz PH Tags: Curr Vasc Pharmacol Source Type: research